Chong Kun Dang Pharmaceutical Corp.
KSC: 185750.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Young-Joo Kim
- Employees
- 2,276
- Headquarters
- Seoul, South Korea
- IPO year
- 2013
- Market cap
- ₩1.1T
- Website
- https://www.ckdpharm.com
Loading 185750…
Loading profile data…Frequently asked questions about 185750
What does Chong Kun Dang Pharmaceutical Corp. (185750.KS) do?
Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insect...
Where does 185750.KS trade?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) trades on the Korea Exchange.
What sector is 185750.KS in?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Chong Kun Dang Pharmaceutical Corp.?
Young-Joo Kim is the chief executive officer of Chong Kun Dang Pharmaceutical Corp. (185750.KS).
Where is Chong Kun Dang Pharmaceutical Corp. headquartered?
Chong Kun Dang Pharmaceutical Corp. is headquartered in South Korea.
Does 185750.KS pay a dividend?
Yes — Chong Kun Dang Pharmaceutical Corp. (185750.KS) paid a trailing twelve-month dividend of KRW 500.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 185750.KS go public?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) completed its initial public offering in 2013.